



ESU course on 'Multidisciplinary approach to the management of genito-urinary cancers: A clinical scenario based interactive session with the experts' at the occasion of the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC)

Place Milan (IT)
Date 24 November 2016, 13.00 – 16.00
Chair K. Touijer, New York (US)

Faculty

A. Bossi, Paris (FR)
P. Ost, Ghent (BE)
J. Palou, Barcelona (ES)
C. Sternberg, Rome (IT)
H. Thoeny, Berne (CH)

13.00 – 14.00 Prostate cancer – 3 clinical cases

13.00 – 13.20 Risk and prognosis assessment

- Clinically-based clinical models
- Genomic-based clinical models
- MRI and MRI fusion biopsy
- Active surveillance
- Indications of focal therapy

13.20 – 13.40 High-risk and locally advanced

- Role of surgery in the multidisciplinary management
- Role of radiation therapy in the multidisciplinary management
- Salvage therapies for disease progression after primary therapy
- Molecular imaging to guide therapy

13.40 – 14.00 Metastatic prostate cancer

- Role of surgery and radiation therapy in the oligometastatic prostate cancer
- Sequential vs. combination therapy: how to maximize benefit from hormonal agents
- Resistance mechanisms to androgen pathway inhibitors
- Role of chemotherapy as an early systemic therapy
- Value of imaging in the decision-making

14.00 – 15.00 Bladder cancer – 2 clinical cases

14.00 – 14.30 Non-muscle invasive bladder cancer

- Quality of TURBT
- Molecular characterization of NIMBC
- Intravesical therapy beyond BCG
- Managing the heterogeneity of T1 urothelial carcinoma

14.30 – 15.00 Muscle invasive bladder cancer and systemic therapy

- Quality metrics for radical cystectomy
- Utilization of neoadjuvant chemotherapy a risk adjusted approach
- Indications for and results of trimodal therapy
- Novel combination therapies for bladder cancer
- Genomic and prognosis of muscle invasive bladder cancer
- Development of targeted agents

15.00 – 16.00 Kidney cancer – 2 clinical cases

15.00 – 15.30 Management of clinically localized renal cortical tumors

- Role of needle biopsy in the era of molecular characterization
- Role of active surveillance
- Volume vs ischemia time in renal function recovery after partial nephrectomy
- Medical vs. surgical chronic kidney disease
- Value of nephrometry score
- Managing the complication of partial nephrectomy

15.30 – 16.00 Advanced renal cell carcinoma

- Novel systemic therapy including immunotherapy for the treatment of advanced RCC
- Metastasectomy and cytoreductive nephrectomy in the targeted therapy era
- Clarification on first and second line systemic therapy
- Stereotactic radiation for metastases
- Clinical application and usefulness of genomic characterization in renal cell carcinoma